




Section: 3. Antiallergics and medicines used in anaphylaxis

		EMLc	ATC codes: H02AB02
Indication	Allergic or hypersensitivity conditions of unspecified type	ICD11 code: 4A8Z	
INN	Dexamethasone		
Medicine type	Chemical agent		
List type	Core (EML) (EMLc)		
Formulations	Oral > Liquid: 0.5 mg per 5 mL (as sodium phosphate) (EMLc) ; 2 mg per 5 mL (as sodium phosphate) Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base) Oral > Solid > tablet: 0.5 mg (as dexamethasone base) ; 0.75 mg (as dexamethasone base) ; 1.5 mg (as dexamethasone base) ; 2 mg (as dexamethasone base) ; 4 mg (as dexamethasone base)		
EML status history	First added in 1984 (TRS 722) Changed in 2007 (TRS 950) Changed in 2025 (TRS 1064)		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more about patents . 		
Wikipedia	Dexamethasone 		
DrugBank	Dexamethasone 		

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of dexamethasone oral liquid 0.5 mg/5 mL (as sodium phosphate) to the EMLc; - the addition of dexamethasone tablets 0.5 mg, 0.75 mg, 1.5 mg and 4 mg (as dexamethasone base) to the EML and EMLc; - to modify the listings to reflect the amount of dexamethasone in terms of dexamethasone salt or dexamethasone base.

